Arkolith/Insider Trading/ZVSA/Form 4

Wolfe Peter

Chief Financial OfficerZyVersa Therapeutics, Inc. (ZVSA) · full profile →Form 4 · filed Dec 14, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
8
1 non-derivative · 7 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 12, 2022Grant(A)42K——42K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 12, 2022Grant(A)10K—$010K
Dec 12, 2022Grant(A)40K—$040K
Dec 12, 2022Grant(A)22K—$022K
Dec 12, 2022Grant(A)10K—$010K
Dec 12, 2022Grant(A)18K—$018K
Dec 12, 2022Grant(A)12K—$012K
Dec 12, 2022Grant(A)22K—$022K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001493152-22-035487) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML